



PHC 2020
January 13 & 14 - 2020
PARIS - Palais des Congrès



**International Conference
on the Management of
Liver Diseases**

Organised by
Pr Patrick Marcellin

Association for the Promotion
of Hepatologic Care (APHC)

Nutrition and NAFLD



Prof. Manuel Romero-Gómez


Digestive Diseases Unit. Virgen del Rocio University Hospital.

SeLiverGI. Institute of Biomedicine of Seville


University of Seville, Seville, Spain.

The mission for today

1. Macro- and micronutrients.
2. Aims of dietary modifications.
3. Mediterranean Diet.
4. Nutritional geometry.
5. Artificial Intelligence for personalized nutritional intervention in NAFLD.




Calories and fats PUFA vs. SFA



Effect of type of fat in hyper-caloric high-fat diet in NAFLD


Dietary intake increase: Body weight modestly increased, not different between groups

OW	N=39	7weeks	RCT
P	SFA	PUFA	
0.45	500±550	632±499	Δ Energy, kcal
0.98	5±6	5±6	Δ Fat, E%




Rosqvist F., Diabetes 2014

N=38 overweighted




Luukkonen PK., Diabetes Care 2018

Changes in IHTG between the groups




Effect of iso-caloric diets

- RCT, 10 weeks
- 67 obese
- Body weight modestly increased, not different between groups







- RCT, 8-weeks
- 45 type-2 diabetes patients
- high-carbohydrate (52% vs. 40%)
- high-MUFA diet (28% vs. 16%/ kcal)
- Body weight remained stable



Olive oil protects against steatohepatitis

n= 5; Scale bars: 200 μm



The dark side of fructose


- n=47 overweight subjects
- Randomized to 4 different test drinks
- 1 L/d for 6 mo

Milk	Coke	
47	106	Carbohydrate (g/L)
15	0	Fat (g/L)
454	430	Energy (kcal/d)




DNL (*De Novo Lipogenesis*)
Reduced satiety
Increased VAT
Increase uric acid
NAFLD

341 NAFLD patients with liver histology data
 Reported fructose-containing beverages consumption



Adjusted age, gender, BMI, total calorie intake, serum lipids, uric acid and HOMA
 Abdelmalek MF., Hepatology 2010


Sucrose-sweetened beverages increase liver fat - RCT



Maersk M., Am J Clin Nutr 2012

- Cross-sectional study in Japan > Short dietary intake questionnaire > NAFLD diagnosed by US
- Fructose from fruits did not increase NAFLD risk i.e. in males (93.9g/1000 kcal/d (68-301.6) decreased NAFLD risk 0.68 (0.42-1.11);p=ns.

Tajima R., Nutrition 2018; Fernandez-Rodriguez C et al. REED 2019







← Twittear



Bring on [#PrecisionMedicine](#) (the drug we all take multiple times a day that needs to be personalized most is food)



High-sugar diet, but not high-fat diet were associated with raised mortality and cardiovascular disease



Antioxidant, Antifibrotic, Immunomodulatory; Lipoprotective

Zinc
Copper
Iron
Selenium
Magnesium
Vitamin A, C, D, E
Choline
Carotenoids
Polyphenols (EVOO)


**Micronutrients deficiency
(low intake, low levels)
linked to NAFLD
Effect in animal models
Supplementation did not
improve NAFLD**

Improving NAFLD at US
Improving ALT/AST
Improving steatosis
NASH resolution
Fibrosis regression
HCC prevention



Vitamin D

- 9 studies • n=5202 NAFLD • n=8520 controls



Eliades M., Aliment Pharmacol Ther 2013

Meta-analysis Vit D in NAFLD: Trials (n=9) comprising 467 participants. **No significant effect of vitamin D supplement** intake on ALT (-2.88 U/L; 95% CI, -6.03 to 0.27; $I^2 = 85\%$), AST (-0.10 U/L; 95% CI, -1.18 to 0.97; $I^2 = 26\%$), and γ -GT (0.12 U/L; 95% CI, -5.94 to 6.18; $I^2 = 38\%$).

Mansour-Ghanaei F, et al. J Diet Suppl 2019:1-19.

Vitamin C

Cross-sectional study
NAFLD by US steatosis,
NASH and fibrosis by
FibroMax (n=714)

Adjusted for: age, gender, energy
intake, BMI, physical activity, SFA
intake, smoking, alcohol, fibers,
cholesterol, red and/or processed
meat intake

Vitamin C > 91.4 UI/1000Kcal (Upper tertile)



N=305
p=0.045


N=225
p=0.004

N=141
p=0.79

Ivancovsky-Wajcman D. & Zelber-Sagi S., Dig Liv Dis 2019

The effectiveness of Vitamin E in NAFLD/NASH clinical trials

Varying quality & Conflicting results




Vitamin E
Lipophilic
antioxidant

Improved steatosis
and steatohepatitis
but not fibrosis

Study	Design	Intervention	Duration	Histology	ALT
Lavine et al. (2011)	RCT	Vit E 800IU + (n=58) Vs. placebo (n=58)	24 mo	+	-
Yakaryilmaz et al.(2007)	OL	Vit E 800mg (n=9)	6 mo	+	+
Dufour et al. (2006)	RCT	Vit E 800IU + UDCA (n=15) Vs. UDCA + placebo (n=18) or placebo + placebo (n=15)	24 mo	+	+
Sanyal et al. (2004)	RCT	Vit E 400IU (n=10) Vs. Vit E+ pioglitazone (n=10)	6 mo	+	-
Vajro et al. (2004)	RCT	Vit E 800>100IU + diet (n=14) Vs. diet + placebo (n=14)	5 mo	●	-
Harrison et al. (2003)	RCT	Vit C+ vit E 1000IU(n=23) Vs. Placebo (n=22)	6 mo	+	-
Kugelmas et al. (2003)	RCT	Diet + aerobic exercise +/- vit E 800IU(n=16)	2 mo	●	+
Hasegawa et al. (2001)	OL	Vit E 300mg (n=22)	12 mo	+	+
Lavine et al. (2000)	OL	Vit E 400-1200mg (n=11)	4-10 mo	●	+

Deficient choline intake is associated with fibrosis in NAFLD patients




- Cross-sectional analysis of 664 NASH patients with liver biopsy
- A food-frequency questionnaire
- Deficient intake defined as 50% AI

Fibrosis		Steatosis		
P	values	P	values	
0.07	1.89 (0.94, 3.79)	0.28	0.68 (0.33, 1.38)	Men ≥14 y old
0.05	2.55 (1.00, 6.48)	0.35	1.57 (0.61, 4.06)	Premenopausal women ≥ 19 yo
0.002	3.37 (1.58, 7.19)	0.74	0.88 (0.42, 1.86)	Postmenopausal women


In conclusion, **decreased choline intake** is associated with worse fibrosis in a subset of patients with NASH; but:

- Is low choline intake associated with low plasma choline concentrations?;
- Is low choline concentrations associated with progression of NAFLD?;
- Could choline supplementation reverse this entity?.



% Weight loss (WL)		5%	7%	10%
NASH-resolution	10%	26%	64%	90%
FIBROSIS-regression	45%	38%	50%	81%
STEATOSIS improvement	35%	65%	76%	100%
% Patients achieving WL	70%	12%	9%	10%

E. Correlations between WL and fibrosis status at the end of intervention




Diet associations with NAFLD in an ethnically diverse population the Multiethnic Cohort

- Nested case-control
- 2,974 NAFLD cases
 - 518 with cirrhosis
 - 2,456 without cirrhosis
- 29,474 matched controls
- Cases identified using Medicare claims ICD9/10
- Controls individually matched to cases on birth year, sex, ethnicity
- FFQ


(g/1,000 kcal/day)	NAFLD No Cirrhosis	NAFLD With Cirrhosis
Q 1 st vs. 4 th	OR (95% CI)	OR (95% CI)
Cholesterol		
≤ 75.4	1.00 (ref.)	1.00 (ref.)
> 121.4	1.09 (0.96-1.23)	1.52 (1.15-2.01)
P-value for trend	0.0889	0.0018
Fiber		
≤ 8.5	1.00 (ref.)	1.00 (ref.)
> 14.0	0.86 (0.75-0.98)	0.75 (0.55-1.02)
P-value for trend	0.0123	0.1018

(g/1,000 kcal/day)	NAFLD No Cirrhosis	NAFLD With Cirrhosis
Q 1 st vs. 4 th	OR (95% CI)	OR (95% CI)
Total red meat		
≤ 13.7	1.00 (ref.)	1.00 (ref.)
> 34.0	1.10 (0.97-1.25)	1.43 (1.08-1.90)
P-value for trend	0.1190	0.0121
Red unprocessed meat		
≤ 9.3	1.00 (ref.)	1.00 (ref.)
> 24.1	1.10 (0.97-1.25)	1.52 (1.15-2.01)
P-value for trend	0.1223	0.0033
Processed red meat		
≤ 3.0	1.00 (ref.)	1.00 (ref.)
> 10.0	1.17 (1.03-1.32)	1.31 (0.99-1.71)
P-value for trend	0.0097	0.1123
Total poultry		
≤ 11.4	1.00 (ref.)	1.00 (ref.)
> 27.6	1.19 (1.05-1.35)	1.03 (0.79-1.35)
P-value for trend	0.0028	0.7717



The Mediterranean diet improves hepatic steatosis RCT

Low Fat Diet	Mediterranean Diet	Nutrient
30% /kcal ω 6 PUFA	40% /kcal MUFA + ω 3 PUFA	fat
50% /kcal	40% /kcal	Carbohydrate
None	Daily	Olive oil & nuts
Fish 2/week, meat daily	Fish 3/w , meat 3/w	Fish & meat



12 NAFLD patients


>> 6-week diets >> 1-2 kg weight loss in both

Benefits of Mediterranean Diet




Lipid metabolism	Inflammation	Insulin Sensitivity
Increases hepatocyte fatty acid oxidation Reduces hepatic lipogenesis Decreases serum triglycerides levels	Anti-inflammatory effect Suppression of pro-inflammatory cytokines	Improves insulin sensitivity

Review

Evaluation of Dietary Approaches for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review

Naba Saeed ¹, Brian Nadeau ¹, Carol Shannon ² and Monica Tincopa ^{1,*}

N=317 patients; 6 RCT




Mediterranean Diet (MD)


- ❖ Extra virgin olive oil
- ❖ Vegetables and Fruits
- ❖ Cereals, legumes, nuts
- ❖ Moderate intakes of fish and other meat, dairy products and red wine
- ❖ Low intakes of eggs and sweets.

↓SFA
 ↑MUFA
 ↑PUFA
 ↑protein vegetables
 ↓sugar fructose
 ↓cholesterol
 ↑fiber
 ↑polyphenols,
 ↑carotenoids


Geometry of nutrition







Green arrows represent nutrients that prevent NAFLD. Red arrows represent nutrients that promote NAFLD. SFAs: saturated fatty acids; Trans FAs: trans fatty acids; ω 3: omega-3 fatty acids; Zn: zinc; Cu: copper; Fe: Iron.



NAFLD: A Dynamic, heterogeneous and multi-axis disease





Macro-micronutrients do affect NAFLD development: Geometry of Nutrition



Combination therapy

Sequential therapy

Measure personal features



Take home messages

1. Dietary modifications have been shown to be effective in NAFLD.
2. Modifications in the composition of specific macro-or micro-nutrients in the diet are not a central point.
3. The Western diet is associated with a greater risk of disease progression in NAFLD while the Mediterranean diet with an improvement in NAFLD.
4. Nutritional geometry can be an excellent tool to study the relationships between the various aspects of diet and NAFLD pathophysiology.
5. The use of algorithms developed by artificial intelligence for personalized nutritional counselling would be useful to prevent and treat NAFLD.

THANK YOU to:



**Shira Zelber-Sagi
Genoveva Barnà
Franz Martin-Bermudo**



@SeLiver_group